MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $280.00M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.55M
Average 0.73M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Definium Therapeutics, Inc. NASDAQ:DFTX | $4.39B | $32.08 | Not rated | -11.0 | +157.49% |
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | $1.39B | $43.01 | Not rated | -21.4 | +153.14% |
GH Research PLC NASDAQ:GHRS | $1.31B | $19.10 | Not rated | -23.8 | +32.87% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | $26.15 | Not rated | -16.2 | -6.16% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
Zevra Therapeutics, Inc. NASDAQ:ZVRA | $540.30M | $9.08 | Overvalued | 6.1 | -3.09% |
Ovid Therapeutics Inc. NASDAQ:OVID | $479.38M | $2.54 | Not rated | -7.1 | +68.18% |
Minerva Neurosciences, Inc. NASDAQ:NERV | $114.62M | $2.30 | Not rated | -0.2 | -49.77% |
Anavex Life Sciences Corp. NASDAQ:AVXL | $86.53M | $0.93 | Not rated | -5.9 | -78.86% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.